Tardive dyskinesia: a review
Related Experiment Video
Updated: Nov 6, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
1Department of Psychiatry, Kelowna General Hospital, British Columbia.
Objective:
To review recent research findings on tardive dyskinesia (TD) with relevance to clinical practice.
Method:
TD is a syndrome of involuntary movements that can occur in association with chronic neuroleptic use. It is of unknown pathophysiology. It can be irreversible, is cosmetically disfiguring, and can be functionally disabling.
Results:
There is as yet no treatment of demonstrated efficacy for TD. It is an iatrogenic disorder whose incidence is increased by age and total cumulative dose of typical neuroleptics. It has been the source of successful litigation in some jurisdictions but, until very recently, there has been no effective antipsychotic agent without this effect.
Conclusion:
This litigation in some jurisdictions has been a major impetus to the development of novel antipsychotic agents. It is less well known that a similar, possibly identical, movement disorder occurs spontaneously particularly in the elderly and in patients with schizophrenia, and that TD is often reversible.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone ll
Parkinson Disease l: Introduction

